Cardiovascular Drugs and Therapy

, Volume 8, Issue 1, pp 101–110 | Cite as

Iron overload cardiomyopathies: New insights into an old disease

  • Peter Liu
  • Nancy Olivieri
Therapeutic Management Of Cardiomyopathy


Iron overload cardiomyopathy is an old disease that has evolved from a rare undiagnosable and untreatable condition to a now much more common, diagnosable, and potentially treatable condition. Pathologically it is due to a direct free iron effect on the myocytes, and not due to interstitial infiltration. This also implies that the disease process is reversible if the tissue iron concentration can be controlled. The advent of magnetic resonance imaging and future genetic identification can identify the population at risk. Chelation therapy, including newer forms of oral chelators, likely will be more commonly available to benefit an ever increasing number and spectrum of the population. Further active research will be needed to improve our pathophysiological understanding and clinical treatment of this increasingly common condition.

Key Words

iron hemochromatosis chelation therapy cardiomyopathy heart failure 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wolfe LC, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.N Engl J Med 1985;312:1600–1603.PubMedGoogle Scholar
  2. 2.
    Niederau C, Fischer R, Sonnenberg A, Steremmel W, Trampisch HJ, Strohmeyer G. The pathogenesis and natural history of primary hemochromatosis.N Engl J Med 1985;313:1256–1262.PubMedGoogle Scholar
  3. 3.
    Cutler DJ, Isner JM, Bracey AW, et al. Hemochromatosis heart disease: An unemphasized cause of potentially reversible restrictive cardiomyopathy.Am J Med 1980;69:923–928.PubMedGoogle Scholar
  4. 4.
    Crosby WH. Hemochromatosis: Current concepts and management.Hosp Prac 1987;25:173–192.Google Scholar
  5. 5.
    Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors.N Engl J Med 1988;318:1355–1362.PubMedGoogle Scholar
  6. 6.
    Klein HG. Transfusions with young erythrocytes (neocytes) in sickel cell anemia.Am J Pediatr Hematol Oncol 1982;4:162–165.PubMedGoogle Scholar
  7. 7.
    Conrad ME. Sickle cell disease and hemochromatosis.Am J Hematol 1991;38:150–152.PubMedGoogle Scholar
  8. 8.
    Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.J Pediatr 1991;118:540–545.PubMedGoogle Scholar
  9. 9.
    Olivieri N, McGee A, Liu P, Koren G, Freedman MH, Benson LN. Cardiac disease-free survival in patients with thalassemia major treated with subcutaneous deferoxamine.Ann NY Acad Sci 1990;612:585–586.Google Scholar
  10. 10.
    Hakim RM, Stivelman JC, Schulman G, et al. Iron overload and mobilization in long-term hemodialysis patients.Am J Kidney Dis 1987;10:293–299.PubMedGoogle Scholar
  11. 11.
    Chan PCK, Liu P, Cronin C, Heathcote J, Uldall R. The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy.Am J Kidney Dis 1992;19:484–489.PubMedGoogle Scholar
  12. 12.
    Dabestani A, Child JS, Henze E, et al. Primary hemochromatosis: Anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy.Am J Cardiol 1984;54:153–159.PubMedGoogle Scholar
  13. 13.
    Olson LJ, Edwards WD, McCall JT, Ilstrup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: Histologic and analytic assessment of 14 hearts from autopsy.J Am Coll Cardiol 1987;10:1239–1243.PubMedGoogle Scholar
  14. 14.
    Cecchetti G, Binda A, Piperno A, Nador F, Fargion S, Fiorelli G. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: Polygraphic and echocardiographic evaluation.Eur Heart J 1991;12:224–230.PubMedGoogle Scholar
  15. 15.
    Aldouri MA, Wanke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassemia patients receiving transfusion and iron chelation: Reversal by intensified chelation.Acta Haematol 1990;84:113–117.PubMedGoogle Scholar
  16. 16.
    Valdes-Cruz LM, Reinecke C, Rutkowski M, et al. Preclinical abnormal segmental cardiac manifestations of thalassemia major in children on transfusion-chelation therapy: Echocardiographic alterations of left ventricular posterior wall contraction and relaxation patterns.Am Heart J 1982;103:505–510.PubMedGoogle Scholar
  17. 17.
    Henry WL, Nienhuis AW, Weiner M, Miller DR, Canale VC, Piomelli S. Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition.Am J Med 1978;64:547–555.PubMedGoogle Scholar
  18. 18.
    Benson L, Liu P, Olivieri N, Rose V, Freedom R. Left ventricular function in young adults with thalassemia.Circulation 1989;80:274.Google Scholar
  19. 19.
    Liu P, Stone J, Collins A, Olivieri N. Is there a predictable relationship between ventricular function and myocardial iron levels in patients with hemochromatosis?Circulation 1993;88:I83.Google Scholar
  20. 20.
    Borow KM, Propper R, Bierman FZ, Grady S, Inati A. The left ventricular end-systolic pressure-dimension relation in patients with thalassemia major A new non-invasive method for assessing contractile state.Circulation 1982;66:980–985.PubMedGoogle Scholar
  21. 21.
    Lynch SR, Skikne BS, Cook JD. Food iron absorption in idiopathic hemochromatosis.Blood 1989;74:2187–2193.PubMedGoogle Scholar
  22. 22.
    Gordeuk V, Mukiibi J, Hasstedt SJ, et al. Iron overload in Africa: Interaction between a gene and dietary iron content.N Engl J Med 1992;326:95–100.PubMedGoogle Scholar
  23. 23.
    Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in thalassemia intermedia.Lancet 1979;2:819–822.PubMedGoogle Scholar
  24. 24.
    Pippard MJ, Weatherall DJ. Iron absorption in non-transfused iron-loading anemias: Prediction of risk of iron loading, and response to iron chelation treatment, in beta-thalassemia intermedia and congenital sideroblastic anemias.Haematologica 1984;17:404–414.Google Scholar
  25. 25.
    Shiloh H, Iancu TC, Bauminger ER, Link G, Pinson A, Hershko C. Deferoxamine-induced iron mobilization and redistribution of myocardial iron in cultured rat heart cells: Studies of the chelatable iron pool by electron microscopy and Mössbauer spectroscopy.J Lab Clin Med 1992;119:428–436.PubMedGoogle Scholar
  26. 26.
    Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance.Am J Med 1971;51:209–221.PubMedGoogle Scholar
  27. 27.
    Garrick LM, Strano-Paul LA, Hoke JE, et al. Tissue iron deposition in untransfused beta-thalassemic mice.Exp Hematol 1989;17:423–428.PubMedGoogle Scholar
  28. 28.
    Link G, Pinson A, Hershko C. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility.J Lab Clin Med 1993;121:127–134.PubMedGoogle Scholar
  29. 29.
    Figueiredo MS, Baffa O, Barbieri Neto J, Zago MA. Liver injury and generation of hydroxyl free radicals in experimental secondary hemochromatosis.Res Exp Med 1993;193:27–37.Google Scholar
  30. 30.
    Mao GD, Thomas PD, Lopaschuk GD, Poznansky MJ. Superoxide dismutase (SOD)-catalase conjugates. Role of hydrogen peroxide and the Fenton reaction in SOD toxicity.J Biol Chem 1993;268:416–420.PubMedGoogle Scholar
  31. 31.
    Voogd A, Sluiter W, van Eijk HG, Koster JF. Low molecular weight iron and the oxygen paradox in isolated rat hearts.J Clin Invest 1992;90:2050–2055.PubMedGoogle Scholar
  32. 32.
    Addison GM, Beamish MR, Hales CN, Hodgkins M, Jacobs A, Llewellin P. An immunoradiometric assay for ferritin in the serum of normal subjects and patients with iron deficiency and iron overload.J Clin Pathol 1972;25:326–329.PubMedGoogle Scholar
  33. 33.
    Green R, Watson LR, Saab GA, Crosby WH. “Normal” serum ferritin: A caution.Blood 1977;50:545–547.PubMedGoogle Scholar
  34. 34.
    Crosby WH. Serum ferritin fails to indicate hemochromatosis: Nothing gold can stay.N Engl J Med 1976;294:1355–1362.PubMedGoogle Scholar
  35. 35.
    Selden C, Peters TJ. The separation and assay of iron proteins in needle biopsy specimens of human liver.Clin Chim Acta 1979;98:47–52.PubMedGoogle Scholar
  36. 36.
    Fitchett DH, Coltart DJ, Littler WA, et al. Cardiac involvement in secondary hemochromatosis: A catheter biopsy study and analysis of myocardium.Cardiovasc Res 1980;14:719–724.PubMedGoogle Scholar
  37. 37.
    Olson LJ, Baldus WP, Tajik AJ. Echocardiographic features of idiopathic hemochromatosis.Am J Cardiol 1987;60:885–889.PubMedGoogle Scholar
  38. 37a.
    Leon MB, Borer JS, Bacharach SL, et al. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload.N Eng J Med 1979;301:1143–148.Google Scholar
  39. 38.
    Rozanski A, Diamond GA, Berman D, et al. Declining specificity of exercise radionuclide ventriculography.N Engl J Med 1983;309:518–522.PubMedGoogle Scholar
  40. 39.
    Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores.N Engl J Med 1982;307:1671–1675.PubMedGoogle Scholar
  41. 40.
    Mitnick JS, Basniak MA, Megibow AJ, et al. CT in beta-thalassemia: Iron deposition in the liver, spleen, and lymph nodes.AJR 1981;136:1191–1194.PubMedGoogle Scholar
  42. 41.
    Long JAJ, Doppman JL, Nienhuis AW, Mills SR. Computed tomographic analysis of beta-thalassemic syndromes with hemochomatosis: Pathologic findings with clinical and laboratory correlations.J Comput Assist Tomogr 1980;4:159–165.PubMedGoogle Scholar
  43. 42.
    Guyader D, Gandon Y, Deugnier Y, et al. Evaluation of computed tomography in the assessment of liver iron overload. A study of 46 cases of idiopathic hemochromatosis.Gastroenterology 1989;97:737–743.PubMedGoogle Scholar
  44. 43.
    Wielopolski L, Zaino EC. Noninvasive in-vivo measurement of hepatic and cardiac iron.J Nucl Med 1992;33:1278–1282.PubMedGoogle Scholar
  45. 44.
    Stark DD, Moseley ME, Bacon BR, et al. Magnetic resonance imaging and spectroscopy of hepatic iron overload.Radiology 1985;154:137–142.PubMedGoogle Scholar
  46. 45.
    Krocker RM, McVeigh ER, Hardy P, Bronskill MJ, Henkelman RM. In-vivo measurement of NMR relaxation times.Magn Reson Med 1985;2:1–13.PubMedGoogle Scholar
  47. 46.
    Gomori JM, Grossman RI, Drott HR. MR relaxation times and iron content of thalassemic spleens: An in vitro study.AJR 1988;150:567–569.PubMedGoogle Scholar
  48. 47.
    Hardy P, Henkelman RM. Transverse relaxation rate enhancement caused by magnetic particles.Magn Reson Imaging 1989;7:265–275.PubMedGoogle Scholar
  49. 48.
    Kiihne S, Thulborn KR, Chang C, et al. Magnetic susceptibility effects in T2 weighted MR images of cerebral hematoma are due to the soluble iron substances.Proc Soc Magn Reson Med 1990;1:14.Google Scholar
  50. 49.
    Kaltwasser JP, Gottschalk R, Schalk KP, Hartl W. Noninvasive quantitation of liver iron-overload by magnetic resonance imaging.Br J Haematol 1990;74:360–363.PubMedGoogle Scholar
  51. 50.
    Johnston DL, Rice L, Vick GW, Hedrick TD, Rokey R. Assessment of tissue iron overload by nuclear magnetic resonance imaging.Am J Med 1989;87:40–47.PubMedGoogle Scholar
  52. 51.
    Lesnefsky EJ, Allen KG, Carrea FP, Horwitz LD. Ironcatalyzed reactions cause lipid peroxidation in the intact heart.J Mol Cell Cardiol 1992;24:1031–1038.PubMedGoogle Scholar
  53. 52.
    Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis.Hepatology 1986;6:24–29.PubMedGoogle Scholar
  54. 53.
    Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults.N Engl J Med 1981;304:319–324.PubMedGoogle Scholar
  55. 54.
    Liu P, Olivieri N, Sullivan H, Henkelman M. Magnetic resonance imaging in beta-thalassemia: Detection of iron content and association with cardiac complications.J Am Coll Cardiol 1993;21:491.Google Scholar
  56. 55.
    Florence A, Ward RJ, Peters TJ, Crichton RR. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.Biochem Pharmacol 1992;44:1023–1027.PubMedGoogle Scholar
  57. 56.
    Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia.Blood 1992;79:2741–2748.PubMedGoogle Scholar
  58. 57.
    Bronspigel-Weintrob N, Olivieri N, Andrews DF, Tyler BJ, Freedman MH, Holland JF. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.N Engl J Med 1990;323:713–719.PubMedGoogle Scholar
  59. 58.
    Olivieri NF, Berriman AM, Tyler BJ, Davis SA, Francombe WH, Liu PP. Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine.Am J Hematol 1992;41:61–63.PubMedGoogle Scholar
  60. 59.
    Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.Lancet 1990;336:1275–1279.PubMedGoogle Scholar
  61. 60.
    Stuhne-Sekalec L, Xu SX, Parkes JG, Olivieri NF, Templeton DM. Speciation of tissue and cellular iron with on-line detection by inductively coupled plasma-mass spectrometry.Anal Biochem 1992;205:278–284.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Peter Liu
    • 1
    • 2
  • Nancy Olivieri
    • 1
    • 2
  1. 1.Centre for Cardiovascular Research and the Division of Cardiology, Toronto HospitalUniversity of TorontoTorontoCanada
  2. 2.Hemoglobinopathy Clinic and the Division of Hematology and Oncology, Hospital for Sick ChildrenUniversity of TorontoTorontoCanada

Personalised recommendations